摘要:
Provided is a chimeric protein comprising neutrophil inhibitory factor, the peptide FRRP specially recognizing the thrombin active site and hirugen. Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, inhibiting platelet aggregation etc.
摘要:
The present invention relates to analogues of anti-thrombin polypeptides and to a process for their preparation. The analogues have been obtained by a C-terminal modification of anti-thrombin polypeptides isolated from the leech Hirudinaria manillensis and are characterized by an improved biological activity in comparison to the polypeptides from which they are derived. The analogues of the invention may be prepared by: 1) isolating the anti-thrombin polypeptide from the tissue or secretions of the leech Hirudinaria manillensis and 2) subsequently modifying the C-terminal end of such polypeptide. Alternatively, the analogues may also be synthetized by recombinant DNA methods. According to this latter aspect, the invention provides DNA sequences, expression vectors and host cell lines for the recombinant preparation of the analogues. The analogues of the invention find a useful application in the treatment of venous thrombosis, vascular shunt occlusion and thrombin-induced disseminated intravascular coagulation.
摘要:
This invention relates to a novel protease-inhibitor, - which we called GELIN - and to pharmaceutical and cosmetic preparations thereof, containing this compound. GELIN is an inhibitor of human and porcine leucocyte elastase and chymotrypsin. GELIN has specific antibiotic properties. It also relates to the novel use of EGLIN, another chymotrypsin-inhibitor in cosmetic preparations.
摘要:
Die Erfindung betrifft ein neues Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten, z. B. Zur Herstellung von Hirudinen, Miniproinsulinen, Leptinen oder Derivaten davon.
摘要:
Die vorliegende Erfindung betrifft ein Verfahren zur Inaktivierung von Carboxypeptidase Y in einer hirudinhaltigen, durch Fermentation einer transformierten Hefe gewonnenen Kulturbrühe, welches sich dadurch auszeichnet, daß die Kulturbrühe unter Durchfluß einer rohrförmigen Apparatur, welche eine Aufheiz-, eine Verweilzeit- und eine Abkühlstrecke aufweist, kontinuierlich auf eine Temperatur von 80 bis 100°C, vorzugsweise 85 bis 95°C, besonders bevorzugt auf eine Temperatur von 85°C erhitzt wird.